Overview

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Status:
Terminated
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer